# US 2014/0194409 A1 · Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194409 A1
- Document ID: US20140194409A1
- Status: Published application
- Kind: A1
- Application number: 14/126,499
- Filed: 2012-06-20
- Published: 2014-07-10
- Earliest claimed: 2011-06-20
- Assignees: H. Lundbeck A/S
- Inventors: René Holm; Lone Bruun
- Web page: https://patentgrep.com/patent/US20140194409A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/4515: having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K31/4545)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6 (depends on 9)

The method of claim 9, wherein the psychosis is schizophrenia Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder or bipolar disorder.

### Claim at position 3

7-8. (canceled)

### Claim 9

A method of treating a patient suffering from a psychosis, comprising Compound (I) semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I).

### Claim at position 5

10-11. (canceled)

### Claim 12 (depends on 9)

The method of claim 9 wherein Compound (I) is administered in combination with one or more neuroleptic agents.

### Claim 13 (depends on 12)

The method of claim 12 wherein the neuroleptic agent is selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.

### Claim 14 (depends on 9)

The method of claim 9, wherein Compound (I) is administered in a dose of between 20 mg and 50 mg per week.

### Claim 15 (depends on 14)

The method of claim 14, wherein Compound (I) is administered in a dose of between 30 mg and 45 mg per week.

### Claim 16 (depends on 15)

The method of claim 15, wherein Compound (I) is administered in a dose of about 30 mg per week.

### Claim 17 (depends on 15)

The method of claim 15, wherein Compound (I) is administered in a dose of about 45 mg per week.

### Claim 18 (depends on 9)

The method of claim 9, wherein the patient suffers from psychosis related to Parkinson's Disease.

### Claim 19 (depends on 9)

The method of claim 9, wherein the psychosis is schizophrenia.